title: Efficacy and Safety of APO866 in Patients With Refractory or Relapsed Cutaneous T-Cell Lymphoma: A Phase 2 Clinical Trial.
authors.affiliation: Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
authors.forename: Simone M
authors.initials: SM
authors.lastname: Goldinger
authors.affiliation: Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland2Private Practice, Feldmeilen, Switzerland.
authors.forename: Sharon
authors.initials: S
authors.lastname: Gobbi Bischof
authors.affiliation: Department of Dermatology, Medical University of Graz, Graz, Austria.
authors.forename: Regina
authors.initials: R
authors.lastname: Fink-Puches
authors.affiliation: Department of Dermatology, University Medical Center Mannheim, University of Heidelberg, Heidelberg, Germany.
authors.forename: Claus-Detlev
authors.initials: CD
authors.lastname: Klemke
authors.affiliation: Department of Dermatology, Nantes University Hospital, Nantes, France.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Dréno
authors.affiliation: Henri Mondor Hospital, Université Paris-Est Créteil Val de Marne (UPEC), Créteil, France.
authors.forename: Martine
authors.initials: M
authors.lastname: Bagot
authors.affiliation: Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland.
authors.forename: Reinhard
authors.initials: R
authors.lastname: Dummer
mesh_terms: D000178:Acrylamides / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D002648:Child; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D009367:Neoplasm Staging; D061214:Patient Safety; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011379:Prognosis; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000178:Acrylamides; C480543:N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide; D010880:Piperidines